Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to issue its quarterly earnings data on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Down 4.9 %

Shares of NRIX stock opened at $16.73 on Wednesday. The stock has a market cap of $1.27 billion, a PE ratio of -5.79 and a beta of 2.14. The business has a 50-day simple moving average of $19.27 and a 200-day simple moving average of $22.08. Nurix Therapeutics has a 52-week low of $9.52 and a 52-week high of $29.56.

Insider Activity

In other news, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NRIX. Morgan Stanley lifted their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Stephens restated an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. Stifel Nicolaus lifted their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, BTIG Research began coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.81.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.